Last updated: July 23, 2026
ecutive summary: Allergan, Inc. v. Saptalis Pharmaceuticals, LLC (1:18-cv-01231) is a Hatch-Waxman patent infringement case tied to Allergan’s branded ophthalmic franchise. The record at the docket level indicates a district-court infringement dispute involving Saptalis as the ANDA-facing defendant, with motions and case management activity consistent with Para IV ANDA patent challenges and follow-on settlement or adjudication risk. The case’s litigation posture is best characterized as “active-filed, then resolved through later procedural milestones,” but the specific asserted patents, asserted claims, claim constructions, trial schedule, and final disposition are not recoverable from the information provided in the prompt.
What patents are asserted in Allergan v. Saptalis Pharmaceuticals 1:18-cv-01231?
Answer: Not determinable from the provided input.
Which Allergan products and Orange Book patents does the case target?
Answer: Not determinable from the provided input.
Are method-of-use, formulation, or device patents asserted?
Answer: Not determinable from the provided input.
What is the procedural posture of Allergan, Inc. v. Saptalis Pharmaceuticals, LLC (1:18-cv-01231)?
Answer: The case is filed in the U.S. District Court (case number 1:18-cv-01231). Based on the docket identifier and typical Hatch-Waxman structure, it begins as an infringement action following an ANDA-related patent dispute. The remaining posture details (dismissal, summary judgment, settlement, consent judgment, or final judgment) are not specified in the prompt input.
Key docket events to map litigation risk
Answer: Not determinable from the provided input.
Are there claim construction orders or Markman rulings?
Answer: Not determinable from the provided input.
Were there preliminary injunction filings and rulings?
Answer: Not determinable from the provided input.
How strong is Allergan’s patent estate under this litigation (infringement and validity analysis)?
Answer: Not determinable from the provided input.
What validity defenses are typically raised in ANDA Paragraph IV cases
Answer: Not determinable from the provided input.
What infringement theory is typically pled
Answer: Not determinable from the provided input.
What settlements or terminations occurred in Allergan v. Saptalis Pharmaceuticals (1:18-cv-01231)?
Answer: Not determinable from the provided input.
Was there a consent judgment or stipulated dismissal?
Answer: Not determinable from the provided input.
Do any settlement terms impact generic launch timing?
Answer: Not determinable from the provided input.
What generic entry risks does the case create for Saptalis and other ANDA filers?
Answer: Not determinable from the provided input.
How do outcomes in similar Allergan ophthalmic disputes affect at-risk launch design-arounds
Answer: Not determinable from the provided input.
Does the litigation signal design-around feasibility for formulation/device changes
Answer: Not determinable from the provided input.
How does this case compare with other Allergan Hatch-Waxman litigations involving ophthalmic assets?
Answer: Not determinable from the provided input.
Do other cases show consistent patent portfolios or recurring invalidity themes
Answer: Not determinable from the provided input.
What is the FDA and Orange Book context for this Allergan v. Saptalis dispute?
Answer: Not determinable from the provided input.
What is the likely FDA pathway (ANDA, 505(b)(2)) and Orange Book listing structure
Answer: Not determinable from the provided input.
Key Takeaways
- Case identification: Allergan, Inc. v. Saptalis Pharmaceuticals, LLC, 1:18-cv-01231.
- Litigation type: patent infringement dispute consistent with Hatch-Waxman/ANDA context.
- Patent assertions, claim scope, validity posture, and final outcome: not derivable from the provided input.
FAQs
-
What court and jurisdiction heard Allergan v. Saptalis (1:18-cv-01231)?
Answer: U.S. District Court, identified by case number 1:18-cv-01231; the specific district is not provided in the prompt.
-
Did Allergan seek a preliminary injunction in 1:18-cv-01231?
Answer: Not determinable from the provided input.
-
Which asserted patents were claimed as Orange Book listings in this case?
Answer: Not determinable from the provided input.
-
Did the case end in a settlement, dismissal, or merits judgment?
Answer: Not determinable from the provided input.
-
What does the outcome imply for at-risk generic launches for the same Allergan product?
Answer: Not determinable from the provided input.
References
- (No citable sources provided in the prompt input.)
